Profile data is unavailable for this security.
About the company
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
- Revenue in USD (TTM)27.42m
- Net income in USD-168.69m
- Incorporated2018
- Employees409.00
- LocationMeiraGTx Holdings PLC655 Third Avenue, Suite 1115NEW YORK 10017United StatesUSA
- Phone+1 (646) 860-7985
- Websitehttps://meiragtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks Holdings Inc | 180.61m | -339.55m | 538.47m | 834.00 | -- | 0.9493 | -- | 2.98 | -6.22 | -6.22 | 3.31 | 9.85 | 0.1353 | -- | 7.80 | 216,554.00 | -25.43 | -68.97 | -27.83 | -75.53 | 72.71 | 66.73 | -188.00 | -409.12 | -- | -- | 0.00 | -- | -9.71 | 33.18 | 38.73 | -- | 23.00 | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 543.92m | 144.00 | -- | -- | -- | 12.35 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -2.45bn | 553.87m | 159.00 | -- | -- | -- | -- | -386.85 | -386.85 | 0.00 | -246.54 | 0.00 | -- | -- | 0.00 | -1,676.47 | -49.21 | -1,891.22 | -52.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8052 | -- | -21.08 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 555.90m | 138.00 | -- | 1.50 | -- | 517.12 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 557.44m | 41.00 | -- | 2.47 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 590.14m | 55.00 | -- | 2.95 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 70.86m | -68.58m | 598.18m | 103.00 | -- | 4.14 | -- | 8.44 | -0.1894 | -0.1894 | 0.1954 | 0.3307 | 0.2689 | 1.06 | 27.10 | 688,000.00 | -26.02 | -55.75 | -29.23 | -66.32 | 99.41 | 95.36 | -96.77 | -1,103.37 | 5.63 | -6.58 | 0.3199 | -- | 2,481.48 | -37.35 | -13.15 | -- | 71.25 | -- |
| MeiraGTx Holdings PLC | 27.42m | -168.69m | 600.46m | 409.00 | -- | -- | -- | 21.90 | -2.11 | -2.11 | 0.343 | -0.5039 | 0.1121 | -- | 9.01 | 71,960.63 | -69.00 | -30.69 | -121.96 | -38.41 | 41.01 | -- | -615.27 | -428.39 | 0.2235 | -36.10 | 2.21 | -- | 137.42 | 20.15 | -75.89 | -- | -11.21 | -- |
| ProKidney Corp | 744.00k | -71.03m | 601.67m | 204.00 | -- | -- | -- | 808.69 | -0.5443 | -0.5443 | 0.0057 | -3.41 | 0.0018 | -- | 0.2347 | 3,647.06 | -38.54 | -- | -- | -- | -- | -- | -21,403.63 | -- | -- | -- | 0.0003 | -- | -- | -- | -72.51 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -237.32m | 605.87m | 166.00 | -- | 16.11 | -- | -- | -2.68 | -2.68 | 0.00 | 0.3916 | 0.00 | -- | -- | 0.00 | -94.37 | -45.17 | -169.95 | -49.01 | -- | -- | -- | -- | -- | -2.19 | 0.4541 | -- | -- | -- | -30.94 | -- | -- | -- |
| Prime Medicine Inc | 5.98m | -197.34m | 622.76m | 214.00 | -- | 3.84 | -- | 104.19 | -1.44 | -1.44 | 0.0434 | 0.8975 | 0.0167 | -- | -- | 27,929.91 | -54.98 | -64.35 | -61.20 | -77.73 | -- | -- | -3,301.64 | -8,356.07 | -- | -- | 0.00 | -- | -- | -- | 1.14 | -- | -- | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 624.94m | 15.00 | -- | 10.06 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -314.85m | 640.76m | 479.00 | -- | 2.94 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| SS Innovations International Inc | 33.57m | -17.11m | 642.82m | 378.00 | -- | 16.21 | -- | 19.15 | -0.0959 | -0.0959 | 0.1822 | 0.2048 | 0.6253 | 1.19 | 5.09 | 88,820.32 | -31.86 | -77.47 | -50.87 | -137.45 | 48.25 | 23.69 | -50.96 | -169.09 | 1.34 | -- | 0.2025 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
| enGene Holdings Inc | 0.00 | -117.30m | 664.49m | 45.00 | -- | 3.08 | -- | -- | -2.29 | -2.29 | 0.00 | 3.22 | 0.00 | -- | -- | 0.00 | -44.05 | -- | -48.27 | -- | -- | -- | -- | -- | -- | -- | 0.1221 | -- | -- | -- | -112.73 | -- | 50.55 | -- |
Data as of Feb 12 2026. Currency figures normalised to MeiraGTx Holdings PLC's reporting currency: US Dollar USD
42.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Dec 2025 | 10.44m | 12.97% |
| Adage Capital Management LPas of 30 Sep 2025 | 4.18m | 5.20% |
| Prosight Management LPas of 30 Sep 2025 | 4.09m | 5.08% |
| Rubric Capital Management LPas of 30 Sep 2025 | 3.73m | 4.63% |
| 683 Capital Management LLCas of 30 Sep 2025 | 2.63m | 3.26% |
| Millennium Management LLCas of 30 Sep 2025 | 2.56m | 3.18% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.39m | 2.97% |
| J. Goldman & Co. LPas of 30 Sep 2025 | 1.80m | 2.24% |
| Knoll Capital Management LPas of 30 Sep 2025 | 1.25m | 1.55% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 1.22m | 1.51% |
More ▼
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
